Rocket Pharmaceuticals In... (RCKT)
The price, the headline numbers and the latest news, in one place.
Rocket Pharmaceuticals Inc. (RCKT) Stock Price, Analysis & Data
| Bid | 2.95 |
| Market Cap | 401.67M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.25M |
| 0.47 | |
| -0.17 | |
| n/a | |
| -2.81 | |
| P/B (ttm) | 1.09 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 4.02 |
| Volume | 3,454,729 |
| Avg. Volume (20D) | 2,195,774 |
| Open | 3.61 |
| Previous Close | 3.62 |
| Day's Range | 3.53 - 3.99 |
| 52-Week Range | 2.53 - 5.45 |
| Analyst | n/a |
| Price Target | 10 (159.07%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), whic...
Financial Performance
In 2025, Rocket Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -223.12M, a decrease of -13.77%.
Financial StatementsAnalyst Forecast
According to 11 analyst ratings, the average rating for RCKT stock is "null". The 12-month stock price forecast is 10, which is upside of 159.07% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.38 misses estimates by -0.65, with 35.59% YoY growth.
Analysts project revenue of ... Upgrade
